Comparing nivolumab response between smokers and ex-smokers in advanced non-small cell lung cancer: It is never too late to quit smoking

Year 2025, Volume: 11 Issue: 6, 1078 - 1087

Mustafa Ersoy

https://doi.org/10.18621/eurj.1733954

Abstract

Objectives: Lung cancer is most commonly caused by smoking, and unfortunately, a significant portion of patients continue to smoke even during their treatment. Our study aimed to investigate the impact of current smoking on the treatment response in patients receiving nivolumab.

Methods: This was a retrospective cohort study that compared the treatment responses of patients who continued to smoke during nivolumab therapy and those who had a history of smoking but had quit prior to nivolumab initiation. The study included 55 patients with advanced non-small cell lung cancer who received treatment between 2019 and 2025. All participants had stage 4 disease and had progressed after initial platinum-based combination chemotherapy. The treatment responses were categorized as progressive disease, stable disease, partial response, and complete response, and the differences between current smokers and ex-smokers were analyzed, with the response evaluation conducted according to the PET Response Criteria in Solid Tumors 1.0 guidelines.

Results: The analysis revealed a statistically significant difference in treatment response between ex-smokers and current smokers (P=0.039). Ex-smokers demonstrated superior Objective Response Rates (56.0% vs. 25.0%) and Disease Control Rates (76.0% vs. 33.3%) compared to current smokers, with the difference in Disease Control Rate reaching statistical significance (P=0.042). Furthermore, multivariate logistic regression indicated that current smokers were 3.64 times less likely to achieve an objective response to nivolumab than ex-smokers, a finding that, while borderline significant, suggests a clinically meaningful trend (P=0.084).

Conclusions: Our study demonstrated that continued smoking during nivolumab therapy may negatively impact the treatment response. While more prospective data is needed, the current results and existing literature suggest that smoking cessation is crucial for patients receiving nivolumab, and clinicians should be more vigilant in addressing this issue.

Keywords

Lung cancer , nivolumab , smoking , ex-smoker

Ethical Statement

This study was approved by the Kütahya Health Sciences University Non-Interventional Clinical Research Ethics Committee (Decision No: 2025/04-39; date: 11.03.2025). All procedures were conducted in accordance with the ethical standards of the institutional and national research committee and with the 1964 Helsinki Declaration and its later amendments. Since this was a retrospective study, informed consent was not obtained from the participants.

References

• 1. Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209-249. doi: 10.3322/caac.21660.
• 2. Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016;387(10027):1540-1550. doi: 10.1016/S0140-6736(15)01281-7.
• 3. Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N Engl J Med. 2015;373(2):123-135. doi: 10.1056/NEJMoa1504627.
• 4. Rittmeyer A, Barlesi F, Waterkamp D, et al; OAK Study Group. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet. 2017;389(10066):255-265. doi: 10.1016/S0140-6736(16)32517-X.
• 5. Wang C, Thudium KB, Han M, et al. In vitro characterization of the anti-PD-1 antibody nivolumab, BMS-936558, and in vivo toxicology in non-human primates. Cancer Immunol Res. 2014;2(9):846-856. doi: 10.1158/2326-6066.CIR-14-0040.
• 6. Walser T, Cui X, Yanagawa J, et al. Smoking and lung cancer: the role of inflammation. Proc Am Thorac Soc. 2008;5(8):811-815. doi: 10.1513/pats.200809-100TH.
• 7. Babb S, Malarcher A, Schauer G, Asman K, Jamal A. Quitting Smoking Among Adults - United States, 2000-2015. MMWR Morb Mortal Wkly Rep. 2017;65(52):1457-1464. doi: 10.15585/mmwr.mm6552a1.
• 8. Balbani AP, Montovani JC. Methods for smoking cessation and treatment of nicotine dependence. Braz J Otorhinolaryngol. 2005;71(6):820-827. doi: 10.1016/s1808-8694(15)31254-4.
• 9. Cataldo JK, Dubey S, Prochaska JJ. Smoking cessation: an integral part of lung cancer treatment. Oncology. 2010;78(5-6):289-301. doi: 10.1159/000319937.
• 10. Duffy SA, Khan MJ, Ronis DL, et al. Health behaviors of head and neck cancer patients the first year after diagnosis. Head Neck. 2008;30(1):93-102. doi: 10.1002/hed.20665.
• 11. Peppone LJ, Mustian KM, Morrow GR, et al. The effect of cigarette smoking on cancer treatment-related side effects. Oncologist. 2011;16(12):1784-1792. doi: 10.1634/theoncologist.2011-0169.
• 12. Videtic GM, Stitt LW, Dar AR, et al. Continued cigarette smoking by patients receiving concurrent chemoradiotherapy for limited-stage small-cell lung cancer is associated with decreased survival. J Clin Oncol. 2003;21(8):1544-1549. doi: 10.1200/JCO.2003.10.089.
• 13. Chellappan S. Smoking Cessation after Cancer Diagnosis and Enhanced Therapy Response: Mechanisms and Significance. Curr Oncol. 2022;29(12):9956-9969. doi: 10.3390/curroncol29120782.
• 14. Luo D, Yang D, Cao D, et al. Effect of smoking status on immunotherapy for lung cancer: a systematic review and meta-analysis. Front Oncol. 2024;14:1422160. doi: 10.3389/fonc.2024.1422160.
• 15. Bianchi F, Le Noci V, Bernardo G, et al. Cigarette smoke sustains immunosuppressive microenvironment inducing M2 macrophage polarization and viability in lung cancer settings. PLoS One. 2024;19(5):e0303875. doi: 10.1371/journal.pone.0303875.
• 16. Desrichard A, Kuo F, Chowell D, et al. Tobacco Smoking-Associated Alterations in the Immune Microenvironment of Squamous Cell Carcinomas. J Natl Cancer Inst. 2018;110(12):1386-1392. doi: 10.1093/jnci/djy060.
• 17. Mehta H, Nazzal K, Sadikot RT. Cigarette smoking and innate immunity. Inflamm Res. 2008;57(11):497-503. doi: 10.1007/s00011-008-8078-6.
• 18. Sardari Nia P, Weyler J, Colpaert C, Vermeulen P, Van Marck E, Van Schil P. Prognostic value of smoking status in operated non-small cell lung cancer. Lung Cancer. 2005;47(3):351-359. doi: 10.1016/j.lungcan.2004.08.011.
• 19. Schaal C, Chellappan SP. Nicotine-mediated cell proliferation and tumor progression in smoking-related cancers. Mol Cancer Res. 2014;12(1):14-23. doi: 10.1158/1541-7786.MCR-13-0541.
• 20. Mennerich D, Kubaichuk K, Kietzmann T. DUBs, Hypoxia, and Cancer. Trends Cancer. 2019;5(10):632-653. doi: 10.1016/j.trecan.2019.08.005.
• 21. Liu H, Yang J, Zhang Y, et al. Psychologic Stress Drives Progression of Malignant Tumors via DRD2/HIF1α Signaling. Cancer Res. 2021;81(20):5353-5365. doi: 10.1158/0008-5472.CAN-21-1043.
• 22. Xu H, Ling M, Xue J, et al. Exosomal microRNA-21 derived from bronchial epithelial cells is involved in aberrant epithelium-fibroblast cross-talk in COPD induced by cigarette smoking. Theranostics. 2018;8(19):5419-5433. doi: 10.7150/thno.27876.
• 23. Jiang X, Liu B, Nie Z, et al. The role of m6A modification in the biological functions and diseases. Signal Transduct Target Ther. 2021;6(1):74. doi: 10.1038/s41392-020-00450-x.
• 24. Lin S, Choe J, Du P, Triboulet R, Gregory RI. The m(6)A Methyltransferase METTL3 Promotes Translation in Human Cancer Cells. Mol Cell. 2016;62(3):335-345. doi: 10.1016/j.molcel.2016.03.021.
• 25. Yang Y, Cheng C, He B, et al. Cigarette smoking, by accelerating the cell cycle, promotes the progression of non-small cell lung cancer through an HIF-1α-METTL3-m6A/CDK2AP2 axis. J Hazard Mater. 2023;455:131556. doi: 10.1016/j.jhazmat.2023.131556.
• 26. Pezzuto A, Citarella F, Croghan I, Tonini G. The effects of cigarette smoking extracts on cell cycle and tumor spread: novel evidence. Future Sci OA. 2019;5(5):FSO394. doi: 10.2144/fsoa-2019-0017.
• 27. Fox JL, Rosenzweig KE, Ostroff JS. The effect of smoking status on survival following radiation therapy for non-small cell lung cancer. Lung Cancer. 2004;44(3):287-293. doi: 10.1016/j.lungcan.2003.11.012.
• 28. Lin CH, Lee HH, Kuei CH, et al. Nicotinic Acetylcholine Receptor Subunit Alpha-5 Promotes Radioresistance via Recruiting E2F Activity in Oral Squamous Cell Carcinoma. J Clin Med. 2019;8(9):1454. doi: 10.3390/jcm8091454.
• 29. Shitara K, Matsuo K, Hatooka S, et al. Heavy smoking history interacts with chemoradiotherapy for esophageal cancer prognosis: a retrospective study. Cancer Sci. 2010;101(4):1001-6. doi: 10.1111/j.1349-7006.2009.01466.x.
• 30. Phi LTH, Sari IN, Yang YG, et al. Cancer Stem Cells (CSCs) in Drug Resistance and their Therapeutic Implications in Cancer Treatment. Stem Cells Int. 2018;2018:5416923. doi: 10.1155/2018/5416923.
• 31. Perumal D, Pillai S, Nguyen J, Schaal C, Coppola D, Chellappan SP. Nicotinic acetylcholine receptors induce c-Kit ligand/Stem Cell Factor and promote stemness in an ARRB1/ β-arrestin-1 dependent manner in NSCLC. Oncotarget. 2014;5(21):10486-10502. doi: 10.18632/oncotarget.2395.
• 32. Guha P, Bandyopadhyaya G, Polumuri SK, et al. Nicotine promotes apoptosis resistance of breast cancer cells and enrichment of side population cells with cancer stem cell-like properties via a signaling cascade involving galectin-3, α9 nicotinic acetylcholine receptor and STAT3. Breast Cancer Res Treat. 2014;145(1):5-22. doi: 10.1007/s10549-014-2912-z.
• 33. O'Malley M, King AN, Conte M, Ellingrod VL, Ramnath N. Effects of cigarette smoking on metabolism and effectiveness of systemic therapy for lung cancer. J Thorac Oncol. 2014;9(7):917-926. doi: 10.1097/JTO.0000000000000191.
• 34. Cortellini A, De Giglio A, Cannita K, et al. Smoking status during first-line immunotherapy and chemotherapy in NSCLC patients: A case-control matched analysis from a large multicenter study. Thorac Cancer. 2021;12(6):880-889. doi: 10.1111/1759-7714.13852.
• 35. Ritterhouse LL, Gogakos T. Molecular Biomarkers of Response to Cancer Immunotherapy. Clin Lab Med. 2022;42(3):469-484. doi: 10.1016/j.cll.2022.05.004.
• 36. Husgafvel-Pursiainen K, Ridanpää M, Anttila S, Vainio H. p53 and ras gene mutations in lung cancer: implications for smoking and occupational exposures. J Occup Environ Med. 1995;37(1):69-76. doi: 10.1097/00043764-199501000-00010.
• 37. Wang X, Christiani DC, Wiencke JK, et al. Mutations in the p53 gene in lung cancer are associated with cigarette smoking and asbestos exposure. Cancer Epidemiol Biomarkers Prev. 1995;4(5):543-548.
• 38. Hellmann M, Rizvi N, Wolchok JD, Chan TA. Genomic profile, smoking, and response to anti-PD-1 therapy in non-small cell lung carcinoma. Mol Cell Oncol. 2015;3(1):e1048929. doi: 10.1080/23723556.2015.1048929.
• 39. Rendon A, Rayi A. Nivolumab. 2024 Feb 28. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–.
• 40. Hodge G, Nairn J, Holmes M, Reynolds PN, Hodge S. Increased intracellular T helper 1 proinflammatory cytokine production in peripheral blood, bronchoalveolar lavage and intraepithelial T cells of COPD subjects. Clin Exp Immunol. 2007;150(1):22-29. doi: 10.1111/j.1365-2249.2007.03451.x.
• 41. Hernandez CP, Morrow K, Velasco C, Wyczechowska DD, Naura AS, Rodriguez PC. Effects of cigarette smoke extract on primary activated T cells. Cell Immunol. 2013;282(1):38-43. doi: 10.1016/j.cellimm.2013.04.005.
• 42. Rizvi NA, Hellmann MD, Snyder A, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015;348(6230):124-128. doi: 10.1126/science.aaa1348.
• 43. Carbone DP, Reck M, Paz-Ares L, et al; CheckMate 026 Investigators. First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer. N Engl J Med. 2017;376(25):2415-2426. doi: 10.1056/NEJMoa1613493.
• 44. Ferris RL, Blumenschein G Jr, Fayette J, et al. Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. N Engl J Med. 2016;375(19):1856-1867. doi: 10.1056/NEJMoa1602252.